AVEO PHARMACEUTICALS, INC. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2022.

Location
Boston, MA
Fiscal year end
31 December
Latest financial report
07 Nov 2022

Quick Takeaways

  • AVEO PHARMACEUTICALS, INC. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q3 2022.
  • Headline metric: Return On Equity -73%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-42%</span>.
  • Most recent SEC facts end date: 03 Nov 2022.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2022-11-03) highlights Return On Equity -72.5%, Return On Assets -27.6%, and Operating Margin -26.0%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

45.5/100

Caution Confidence high

Return On Equity

-73%

Metric score 0.0/100

Return On Assets

-28%

Metric score 0.0/100

Financial Health

Current Ratio
2.37x
Quick Ratio
2.27x
Debt to Equity
1.83x

Strengths

Current Ratio, Revenues YoY, and NetIncomeLoss YoY

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Return On Equity

-73%

YoY: -42%

Industry median: -43% (n=675)

View history

Return On Assets

-28%

YoY: -56%

Industry median: -47% (n=673)

View history

Operating Margin

-26%

YoY: -88%

Industry median: -121% (n=298)

View history

Current Ratio

2.37x

YoY: -51%

Industry median: 3.39x (n=667)

View history

Quick Ratio

2.27x

YoY: -50%

Industry median: 1.51x (n=289)

View history

Debt-to-equity

1.83x

YoY: +104%

Industry median: 0.26x (n=530)

View history

Revenues YoY

269%

YoY:

Industry median: 7.3% (n=302)

View history

NetIncomeLoss YoY

50%

YoY:

Industry median: -0.93% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity -73% -42%
Return On Assets -28% -56%
Operating Margin -26% -88%

Financial Health

Metric Latest value YoY change
Current Ratio 2.37x -51%
Quick Ratio 2.27x -50%
Debt-to-equity 1.83x +104%

Growth

Metric Latest value YoY change
Revenues YoY 269%
NetIncomeLoss YoY 50%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 34,763,127 +1.1%
Common Stock, Shares, Outstanding 34,621,112 +0.72%
Common Stock, Value, Issued $35,000 +2.9%
Weighted Average Number of Shares Outstanding, Basic 34,618,000 +0.71%
Weighted Average Number of Shares Outstanding, Diluted 34,618,000 +0.71%

Additional Metrics

Metric Latest value YoY change
Revenue from Contract with Customer, Excluding Assessed Tax $94,319,000 +269%
Research and Development Expense $39,673,000 +60%
Costs and Expenses $118,812,000 +46%
Operating Income (Loss) $24,493,000 +56%
Nonoperating Income (Expense) $4,546,000 -203%
Earnings Per Share, Basic -1 +57%
Earnings Per Share, Diluted -1 +57%
Cash and Cash Equivalents, at Carrying Value $77,398,000 +12%
Accounts Receivable, after Allowance for Credit Loss, Current $18,717,000 +125%
Inventory, Net $1,106,000 -12%
Assets, Current $100,731,000 -6.7%
Property, Plant and Equipment, Net $225,000 -23%
Operating Lease, Right-of-Use Asset $32,000 -94%
Other Assets, Noncurrent $245,000 -5%
Assets $101,233,000 -7.2%
Accounts Payable, Current $5,039,000 +2.3%
Employee-related Liabilities, Current $5,728,000 +38%
Contract with Customer, Liability, Current $0 -100%
Liabilities, Current $42,423,000 +90%
Other Liabilities, Noncurrent $2,780,000 +14%
Liabilities $72,388,000 +25%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0
Retained Earnings (Accumulated Deficit) $696,331,000 -4.4%
Stockholders' Equity Attributable to Parent $28,845,000 -44%
Liabilities and Equity $101,233,000 -7.2%
Common Stock, Shares Authorized 80,000,000 +60%
Common Stock, Shares, Issued 34,621,112 +0.72%
Common Stock, Par or Stated Value Per Share 0 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $77,398,000 +12%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $29,037,000 +50%
Operating Lease, Liability, Current $2,000 -99%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 5,000,000 0%
Additional Paid in Capital $725,141,000 +0.92%
Preferred Stock, Shares Outstanding 0
Share-based Payment Arrangement, Expense $5,527,000 +25%
Preferred Stock, Par or Stated Value Per Share 0 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY